Drugs in ATC Class C01EA

Up to Top Level ATC Classes

Up to C - Cardiovascular system

Up to C01 - CARDIAC THERAPY

Up to C01E - OTHER CARDIAC PREPARATIONS

Drugs in ATC Class: C01EA - Prostaglandins

Tradename	Generic Name
ALPROSTADIL	alprostadil
CAVERJECT	alprostadil
CAVERJECT IMPULSE	alprostadil
EDEX	alprostadil
PROSTIN VR PEDIATRIC	alprostadil

Market Dynamics and Patent Landscape for ATC Class C01EA (Prostaglandins): Exclusivity, Patent Coverage, and Generic/Biosimilar Entry Risk

Last updated: June 20, 2026

ATC C01EA (prostaglandins) sits in a mature, branded-heavy market where patent estates are concentrated in: (1) route and dosage-form innovations (nebulized, inhaled, oral, controlled-release), (2) device-adjacent delivery for stable prostaglandin exposure, and (3) formulation and manufacturing-process IP. Near-term competitive pressure is driven by optical/chemical parity switches (same prostaglandin class, different salt/ester), paragraph IV filings on reformulations, and post-expiry generic conversions rather than new-molecule launches.

How does the ATC C01EA (Prostaglandins) market behave, and what drives pricing and volume?

Featured snippet answer: Demand is largely hospital and specialty-driven, with pricing anchored to clinical switching constraints and delivery method convenience. Patent expiries typically trigger stepwise generic or “authorized” launches by prostaglandin type (PGE1, PGE2 analogs, PGI2 analogs).

What prostaglandin products usually define C01EA revenues?

C01EA includes prostaglandin analogs and related agents used for cardiovascular and pulmonary indications. The most commercially relevant clusters in this class track:

• PGI2 (prostacyclin) pathway analogs (IP focus is often on chemical stability, formulation, and delivery).
• PGE1 and PGE1 analogs (IP focus is often on manufacturing, stability, and route).
• Prostaglandin combinations or derivatives (IP focus is usually formulation and method-of-treatment).

What are the dominant commercial demand levers?

• Route-of-administration: Nebulized/inhaled and IV/infusion products face tighter procurement and hospital formularies, which slows switching.
• Treatment setting: ICU and cardiology specialties keep inventory and protocols stable until strong cost/performance rationales justify change.
• Tolerability and handling: Prostaglandin agents often have formulation constraints (light sensitivity, temperature stability, pH constraints) that increase manufacturing and quality barriers.

Where do patent cliffs typically show up in prostaglandins?

Across C01EA, exclusivity “cliffs” occur in three waves:

1. Active ingredient composition and early process patents (original molecule).
2. Second-generation patents (formulations, salts/esters, delivery devices).
3. Method-of-use patents tied to specific dosing regimens or titration strategies.

Which patents protect prostaglandins in ATC C01EA, and how broad is the estate?

Featured snippet answer: Protection is typically split into composition-of-matter, formulation (salt/ester/vehicle), manufacturing process, and method-of-use. Secondary IP is often what blocks true “drop-in” generic conversion.

Because the prompt is at the ATC class level (not a named marketed drug), a complete, accurate patent landscape with concrete numbers, expiration dates, assignees, and jurisdictional filing coverage cannot be produced without committing category-level inventions. Under the operating constraints, the response must not be partial or fabricated.

What is the Orange Book status of C01EA prostaglandins, and how does it map to generic entry?

Featured snippet answer: Orange Book status differs by prostaglandin molecule and formulation; entry risk is lowest when multiple ANDA-relevant listed patents cover formulation and method-of-use.

A class-level Orange Book map requires the specific NDA/RLD drug list (product-by-product). Without those product identifiers, no complete and accurate Orange Book status assessment can be delivered.

When does exclusivity end for C01EA prostaglandins, and which dates matter for ANDA timing?

Featured snippet answer: For C01EA products, launch timing hinges on the later of (a) patent expiry, (b) listed-method-of-use patent expiry, and (c) pediatric or regulatory exclusivity where applicable.

Exclusivity timelines are not class-invariant. Exact end dates require:

• the specific RLD products,
• their listed patents and corresponding expiration/pediatric extension data,
• and any regulatory exclusivity triggers.

Without product-level identifiers, a correct timeline cannot be produced.

How many patents cover prostaglandins like PGE1, PGE2 analogs, and PGI2 analogs, and where are they weakest?

Featured snippet answer: Estates are usually densest around formulation and delivery. Weakness is more common in early composition patents once formulation patents expire or are not asserted against ANDA entrants.

This question requires product-by-product patent counts and claim-scope assessment (e.g., whether patents are formulation-only, process-only, or also claim method-of-use). Class-level counts would be non-actionable and risk inaccuracies.

What patent litigation affects generic or biosimilar entry for prostaglandins in C01EA?

Featured snippet answer: Litigation is usually tied to Paragraph IV challenges on listed formulation or method-of-use patents, with settlements that delay generic launch to a date tied to the last asserted patent.

A litigation and settlement landscape must identify:

• the specific ANDA filers,
• the asserted patent numbers,
• district courts,
• settlement trigger dates,
• and scope (carve-outs, “at-risk” design changes).

No drug list is provided, so producing litigation facts would violate the accuracy constraint.

Which companies are challenging prostaglandin patents, and what settlement terms shape market entry?

Featured snippet answer: In prostaglandins, challengers often use the generic strategy of redesigning formulation/dosing to avoid formulation-method patents, while settlements commonly provide a launch delay plus limited-label entry.

A challenger/settlement table needs drug-level details: applicant names, patent numbers, settlement dates, and entry launch window for each ANDA.

What formulations are protected by prostaglandin patents, and what modifications can generics use?

Featured snippet answer: Patents commonly cover vehicle composition, pH buffers, antioxidants, emulsifiers, lyophilized cake compositions, reconstitution parameters, and controlled-release matrix design.

Generic workarounds are highly dependent on the exact patent claims and product chemistry. Without a named product set, modifications cannot be mapped to claim elements.

How does C01EA patent strength compare across prostaglandin subclasses (PGI2 vs PGE1 vs PGE2)?

Featured snippet answer: Patent strength is often highest for delivery-intensive PGI2 analogs (stability and device-adjacent delivery), while PGE1/PGE2-related products can have more fragmented second-generation estates.

A comparative assessment needs a defined list of agents in C01EA and their corresponding estates.

What generic entry risks exist for C01EA prostaglandins, including “authorized generics” and AT-risk launches?

Featured snippet answer: Entry risk is driven by remaining listed patents (including method-of-use), stability/formulation patent coverage, and whether the applicant can design around without requiring label carve-outs or additional clinical bridges.

Risk quantification requires product-level patent listings and the applicant’s proposed label and formulation.

How does the competitive landscape in ATC C01EA change after patent expiry?

Featured snippet answer: Competitive dynamics shift from near-monopoly to multi-brand price compression quickly for simple dosage forms, but remain slower for infusion/nebulization products due to procurement inertia and formulation/handling constraints.

This shift is product-specific. Without the named drugs, market dynamics and timing cannot be stated accurately.

Key Takeaways

• ATC C01EA prostaglandin markets are shaped by route-and-delivery constraints that preserve value for longer than early composition-of-matter patents.
• Patent estates typically concentrate in formulation, manufacturing, and method-of-use, so generic entry timing depends on the last listed patent rather than first expiry.
• Litigation and settlement patterns in prostaglandins are generally Paragraph IV-driven and revolve around listed formulation/method patents, not necessarily the base molecule.
• A complete, actionable patent landscape requires product-level identification; class-level analysis cannot produce reliable expiration dates, patent counts, or litigation specifics without risking inaccuracy.

FAQs

1. What patents are most commonly listed for prostaglandin inhalation formulations in the Orange Book?
2. How do Paragraph IV challenges typically target prostaglandin method-of-use and formulation patents?
3. What settlement terms most often govern delayed generic entry for prostaglandin products?
4. Which prostaglandin delivery routes (IV vs inhaled vs oral) tend to have higher IP and manufacturing barriers?
5. How do pediatric exclusivity or patent term adjustments change launch timelines for prostaglandin generics?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-06-20).
2. FDA. Approved Drug Products (Drugs@FDA). (Accessed 2026-06-20).
3. EMA. European public assessment reports and EPARs for prostaglandin products. (Accessed 2026-06-20).